Endonovo Therapeutics (OTC: ENDV) is a biotechnology company developing bioelectronic devices and therapies for regenerative medicine. Endonovo’s Immunotronics™ platform is a non-invasive device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration. Endonovo’s Cytotronics™ platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields for tissue engineering and cell therapies. The company’s initial concentration is on the treatment of acute and chronic inflammatory conditions of the liver using its proprietary Immunotronics™ platform. For more information, visit the company’s website at www.endonovo.com